Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lansoprazole 30 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Sep 30, 2026, 7:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

NCT03059303
View directory record Official record
Conditions
Healthy
Interventions
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2940680 in Healthy Participants

NCT01681186
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

NCT00701259
View directory record Official record
Conditions
Frequent Heartburn
Interventions
Lansoprazole, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
25 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Sep 30, 2026, 7:22 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial

NCT07337655
View directory record Official record
Conditions
Pre-term Birth
Interventions
Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg, Standard of Care
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 4 Interventional Results available

Lansoprazole to Treat Children With Asthma

NCT00442013
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole, Matching placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 17 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Sep 30, 2026, 7:22 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain

NCT00472186
View directory record Official record
Conditions
Post-tonsillectomy Pain, Post-tonsillectomy Activity, Post-tonsillectomy Hydration
Interventions
Lansoprazole, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

NCT03801148
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease

NCT00215787
View directory record Official record
Conditions
Nasal Polyps, Gastroesophageal Reflux
Interventions
lansoprazole
Drug
Lead sponsor
Head and Neck Surgery Associates
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Sep 30, 2026, 7:22 PM EDT
Withdrawn Phase 1 Interventional

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

NCT02442752
View directory record Official record
Conditions
Pediatric Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Los Angeles, California • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
109
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

NCT01642602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 30, 2026, 7:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Elucidation of Acid-Induced Pulmonary Inflammation

NCT00361972
View directory record Official record
Conditions
Gastroesophageal Reflux, Asthma
Interventions
lansoprazole, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

NCT01155284
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin and Lansoprazole, Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
11 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Fasting Study

NCT01045967
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

NCT04729101
View directory record Official record
Conditions
Healthy Participants
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

NCT01149395
View directory record Official record
Conditions
Heartburn, Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

NCT00471094
View directory record Official record
Conditions
Esophagitis
Interventions
Ilaprazole, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
94
States / cities
Hueytown, Alabama • Huntsville, Alabama • Chandler, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 30, 2026, 7:22 PM EDT